Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy

Seminars in Radiation Oncology

Volumn 18, Issue 2, 2008, Pages 136-148

  Nimmagadda, Sridhar ^a   Ford, Eric C ^b   Wong, John W ^b   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE; FLUORODEOXYGLUCOSE F 18; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PHOSPHORYLCHOLINE; SYNAPTOTAGMIN; THYMIDINE PHOSPHORYLASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL PROLIFERATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA SYNTHESIS; DOSE RESPONSE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENOME; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; LUNG CANCER; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; OUTCOME ASSESSMENT; OXYGEN CONCENTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY; RADIATION MONITORING; RADIATION RESPONSE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE PERFUSION;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY, INTERVENTIONAL; RADIOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 39749173788     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.10.009     Document Type: Article

References (206)

1. Olive K.P., and Tuveson D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 1512 (2006) 5277-5287
2. Sharpless N.E., and Depinho R.A. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5 (2006) 741-754
3. Singh M., and Johnson L. Using genetically engineered mouse models of cancer to aid drug development: An industry perspective. Clin Cancer Res 1512 (2006) 5312-5328
4. Van Dyke T., and Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 25108 (2002) 135-144
5. Pomper M.G. Molecular imaging: An overview. Acad Radiol 8 (2001) 1141-1153
6. Pomper M.G. Translational molecular imaging for cancer. Cancer Imaging 5 Spec No A (2005) S16-S26
7. Pomper M.G., Phillips E., Fan H., et al. Synthesis and biodistribution of radiolabeled {alpha}7 nicotinic acetylcholine receptor ligands. J Nucl Med 46 (2005) 326-334
8. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 117 (2003) 545-580
9. Gelovani Tjuvajev J., and Blasberg R.G. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 3 (2003) 327-332
10. Warburg O. On the origin of cancer cells. Science 24123 (1956) 309-314
11. Ak I., Stokkel M.P., and Pauwels E.K. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 126 (2000) 560-574
12. Pauwels E.K., Sturm E.J., Bombardieri E., et al. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126 (2000) 549-559
13. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 suppl (2001) 1S-93S
14. van Baardwijk A., Baumert B.G., Bosmans G., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
15. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 159 (2004) 78-86
16. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 1551 (2001) 923-931
17. Gondi V., Bradley K., Mehta M., et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 167 (2007) 187-195
18. Andrade R.S., Heron D.E., Degirmenci B., et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 165 (2006) 1315-1322
19. Gregoire V., Bol A., Geets X., and Lee J. Is PET-based treatment planning the new standard in modern radiotherapy?. The head and neck paradigm. Semin Radiat Oncol 16 (2006) 232-238
20. Tralins K.S., Douglas J.G., Stelzer K.J., et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: Prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43 (2002) 1667-1673
21. Sakurai H., Suzuki Y., Nonaka T., et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy-Tumor volume and FDG uptake value. Gynecol Oncol 100 (2006) 601-607
22. Cascini G.L., Avallone A., Delrio P., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47 (2006) 1241-1248
23. Westerterp M., van Westreenen H.L., Reitsma J.B., et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-Systematic review. Radiology 236 (2005) 841-851
24. Kasamon Y.L., Jones R.J., and Wahl R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48 suppl 1 (2007) 19S-27S
25. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80 suppl (1997) 2505-2509
26. Ford E.C., Kinahan P.E., Hanlon L., et al. Tumor delineation using PET in head and neck cancers: Threshold contouring and lesion volumes. Med Phys 33 (2006) 4280-4288
27. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 120 (2002) 1398-1404
28. Allal A.S., Slosman D.O., Kebdani T., et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 159 (2004) 1295-1300
29. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 (2002) 127-135
30. Cerfolio R.J., Ojha B., Mukherjee S., et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 125 (2003) 938-944
31. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 121 (2003) 1285-1292
32. Rege S., Safa A.A., Chaiken L., et al. Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 23 (2000) 164-169
33. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 1521 (2003) 2651-2657
34. Hautzel H., and Muller-Gartner H.W. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38 (1997) 1384-1386
35. Yao M., Graham M.M., Smith R.B., et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. Int J Radiat Oncol Biol Phys 160 (2004) 1410-1418
36. Erdi Y.E., Macapinlac H., Rosenzweig K.E., et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27 (2000) 861-866
37. Charnley N., West C.M., Barnett C.M., et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 166 (2006) 331-338
38. Rozental J.M., Levine R.L., Mehta M.P., et al. Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 20 (1991) 1053-1060
39. Spence A.M., Muzi M., Graham M.M., et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome. Clin Cancer Res 8 (2002) 971-979
40. Kubota R., Yamada S., Kubota K., et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33 (1992) 1972-1980
41. Arslan N., Miller T.R., Dehdashti F., et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4 (2002) 301-310
42. Pugachev A., Ruan S., Carlin S., et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 162 (2005) 545-553
43. Ford E., Lavely W., Frassica D., et al. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation, submitted. Int J Radiat Oncol Biol Phys (2007) (in press)
44. Busch H., Davis J.R., Honig G.R., et al. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 19 (1959) 1030-1039
45. Isselbacher K.J. Sugar and amino acid transport by cells in culture-Differences between normal and malignant cells. N Engl J Med 27286 (1972) 929-933
46. Laverman P., Boerman O.C., Corstens F.H., et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 29 (2002) 681-690
47. Jager P.L., Vaalburg W., Pruim J., et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
48. Kuwert T., Morgenroth C., Woesler B., et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 23 (1996) 1345-1353
49. Ogawa T., Shishido F., Kanno I., et al. Cerebral glioma: Evaluation with methionine PET. Radiology 186 (1993) 45-53
50. Yoshimoto M., Waki A., Obata A., et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Biol 31 (2004) 859-865
51. Mankoff D.A., Shields A.F., and Krohn K.A. PET imaging of cellular proliferation. Radiol Clin North Am 43 (2005) 153-167
52. Kenny L.M., Aboagye E.O., and Price P.M. Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol) 16 (2004) 176-185
53. Shields A.F., Coonrod D.V., Quackenbush R.C., et al. Cellular sources of thymidine nucleotides: Studies for PET. J Nucl Med 28 (1987) 1435-1440
54. Quackenbush R.C., and Shields A.F. Local re-utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine. Cell Tissue Kinet 21 (1988) 381-387
55. Shields A.F., Lim K., Grierson J., et al. Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med 31 (1990) 337-342
56. Shields A.F., Graham M.M., Kozawa S.M., et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 33 (1992) 581-584
57. Mankoff D.A., Shields A.F., Graham M.M., et al. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 37 (1996) 2049-2057
58. Shields A.F., Mankoff D., Graham M.M., et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med 37 (1996) 290-296
59. Mankoff D.A., Shields A.F., Graham M.M., et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. J Nucl Med 39 (1998) 1043-1055
60. Sherley J.L., and Kelly T.J. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 5263 (1988) 375-382
61. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
62. Visvikis D., Francis D., Mulligan R., et al. Comparison of methodologies for the in vivo assessment of (18)FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 31 (2003) 169-178
63. Choi S.J., Kim J.S., Kim J.H., et al. [(18)F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32 (2005) 653-659
64. Buck A.K., Halter G., Schirrmeister H., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44 (2003) 1426-1431
65. Kenny L., Coombes R.C., Vigushin D.M., et al. Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 (2007) 1139-1347
66. Sugiyama M., Sakahara H., Sato K., et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 45 (2004) 1754-1758
67. Apisarnthanarax S., Alauddin M.M., Mourtada F., et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 112 (2006) 4590-4597
68. Yang Y.J., Ryu J.S., Kim S.Y., et al. Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33 (2006) 412-419
69. Sun H., Sloan A., Mangner T.J., et al. Imaging DNA synthesis with [(18)F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 32 (2005) 15-22
70. Nimmagadda S., Mangner T.J., Sun H., et al. Biodistribution and radiation dosimetry estimates of 1-(2′-deoxy-2′-18F-fluoro-1-{beta}-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. J Nucl Med 46 (2005) 1916-1922
71. Glunde K., Jacobs M.A., and Bhujwalla Z.M. Choline metabolism in cancer: Implications for diagnosis and therapy. Expert Rev Mol Diagn 6 (2006) 821-829
72. Zheng Q.H., Stone K.L., Mock B.H., et al. [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol 29 (2002) 803-807
73. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
74. Hara T., Kosaka N., Shinoura N., et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 38 (1997) 842-847
75. DeGrado T.R., Baldwin S.W., Wang S., et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42 (2001) 1805-1814
76. DeGrado T.R., Coleman R.E., Wang S., et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 161 (2001) 110-117
77. Hara T., Bansal A., and Degrado T.R. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5 (2006) 498-509
78. Breeuwsma A.J., Pruim J., Jongen M.M., et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 32 (2005) 668-673
79. Al-Saeedi F., Welch A.E., and Smith T.A. [methyl-3H]Choline incorporation into MCF7 tumour cells: Correlation with proliferation. Eur J Nucl Med Mol Imaging 32 (2005) 660-667
80. Pathak A.P., Gimi B., Glunde K., et al. Molecular and functional imaging of cancer: Advances in MRI and MRS. Methods Enzymol 386 (2004) 3-60
81. Gillies R.J., and Morse D.L. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 7 (2005) 287-326
82. Glunde K., Ackerstaff E., Mori N., Jacobs M.A., and Bhujwalla Z.M. Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions. Mol Pharm 3 (2006) 496-506
83. Lichy M.P., Bachert P., Hamprecht F., et al. [Application of (1)H MR spectroscopic imaging in radiation oncology: Choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors]. Rofo 178 (2006) 627-633
84. Zeng Q.S., Li C.F., Liu H., et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 168 (2007) 151-158
85. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 1549 (2001) 1171-1182
86. Popple R.A., Ove R., and Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 154 (2002) 921-927
87. Bussink J., Kaanders J.H., Rijken P.F., et al. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 153 (2000) 398-404
88. Cowen R.L., Williams K.J., Chinje E.C., et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res 1564 (2004) 1396-1402
89. Greco O., Joiner M.C., Doleh A., et al. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther 13 (2006) 206-215
90. Lipnik K., Greco O., Scott S., et al. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology 25349 (2006) 121-133
91. Padhani A.R., Krohn K.A., Lewis J.S., et al. Imaging oxygenation of human tumours. Eur Radiol 17 (2007) 861-872
92. Rajendran J.G., and Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43 (2005) 169-187
93. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 1512 (2006) 5435-5441
94. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
95. Dubois L., Landuyt W., Haustermans K., et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2991 (2004) 1947-1954
96. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 3033 (1995) 391-398
97. Rajendran J.G., Mankoff D.A., O'Sullivan F., et al. Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 110 (2004) 2245-2252
98. Rajendran J.G., Wilson D.C., Conrad E.U., et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30 (2003) 695-704
99. Cook G.J., Houston S., Barrington S.F., et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG. J Nucl Med 39 (1998) 99-103
100. Zhang X., Melo T., Ballinger J.R., et al. Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 142 (1998) 737-740
101. Fujibayashi Y., Taniuchi H., Yonekura Y., et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
102. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
103. Dehdashti F., Grigsby P.W., Mintun M.A., et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-A preliminary report. Int J Radiat Oncol Biol Phys 155 (2003) 1233-1238
104. Matsumoto K., Szajek L., Krishna M.C., et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 30 (2007) 873-881
105. Lewis J., Laforest R., Buettner T., et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci U S A 98 (2001) 1206-1211
106. Obata A., Kasamatsu S., Lewis J.S., et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 32 (2005) 21-28
107. Aft R.L., Lewis J.S., Zhang F., Kim J., et al. Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res 163 (2003) 5496-5504
108. Burgman P., O'Donoghue J.A., Lewis J.S., et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 32 (2005) 623-630
109. Zanzonico P., O'Donoghue J., Chapman J.D., et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 31 (2004) 117-128
110. Beck R., Roper B., Carlsen J.M., et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 48 (2007) 973-980
111. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5 (2005) 231-237
112. Meyn R.E., Stephens L.C., and Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev 15 (1996) 119-131
113. Boersma H.H., Kietselaer B.L., Stolk L.M., et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med 46 (2005) 2035-2050
114. Yagle K.J., Eary J.F., Tait J.F., et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46 (2005) 658-666
115. Blankenberg F.G., Katsikis P.D., Tait J.F., et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 40 (1999) 184-191
116. Keen H.G., Dekker B.A., Disley L., et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 32 (2005) 395-402
117. Belhocine T., Steinmetz N., Hustinx R., et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8 (2002) 2766-2774
118. Haas R.L., de Jong D., Valdes Olmos R.A., et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 159 (2004) 782-787
119. Petrovsky A., Schellenberger E., Josephson L., et al. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 1563 (2003) 1936-1942
120. Ntziachristos V., Schellenberger E.A., Ripoll J., et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A 101 (2004) 12294-12299
121. Davletov B.A., and Sudhof T.C. A single C2 domain from synaptotagmin I is sufficient for high affinity Ca2+/phospholipid binding. J Biol Chem 15268 (1993) 26386-26390
122. Zhao M., Beauregard D.A., Loizou L., et al. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 7 (2001) 1241-1244
123. Massie C., and Mills I.G. The developing role of receptors and adaptors. Nat Rev Cancer 6 (2006) 403-409
124. Srinivasan D.M., Kapoor M., Kojima F., et al. Growth factor receptors: Implications in tumor biology. Curr Opin Investig Drugs 6 (2005) 1246-1249
125. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 26339 (1998) 1609-1618
126. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2024 (2006) 2793-2799
127. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 (1995) 1766-1774
128. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 (2005) 344-350
129. Iznaga-Escobar N., Torres L.A., Morales A., et al. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med 39 (1998) 15-23
130. Ramos-Suzarte M., Rodriguez N., Oliva J.P., et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 40 (1999) 768-775
131. Ke S., Wen X., Gurfinkel M., et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 1563 (2003) 7870-7875
132. Mishani E., Abourbeh G., Rozen Y., et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 31 (2004) 469-476
133. Pal A., Glekas A., Doubrovin M., et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8 (2006) 262-277
134. Wang J.Q., Gao M., Miller K.D., et al. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 116 (2006) 4102-4106
135. Hynes N.E., and Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
136. Cooke T., Reeves J., Lanigan A., et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12 suppl 1 (2001) S23-S28
137. Robinson M.K., Doss M., Shaller C., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res Feb 1565 (2005) 1471-1478
138. Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol May 2024 (2006) 2276-2282
139. Krenning E.P., Bakker W.H., Kooij P.P., et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33 (1992) 652-658
140. Anderson C.J., Dehdashti F., Cutler P.D., et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42 2 (2001) 213-221
141. Henze M., Schuhmacher J., Hipp P., et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42 7 (2001) 1053-1056
142. Gabriel M., Decristoforo C., Kendler D., et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48 (2007) 508-518
143. Moore A., Josephson L., Bhorade R.M., et al. Human transferrin receptor gene as a marker gene for MR imaging. Radiology 221 (2001) 244-250
144. Artemov D., Mori N., Okollie B., et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49 (2003) 403-408
145. Artemov D., Mori N., Ravi R., et al. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 163 (2003) 2723-2727
146. Penuelas I., Haberkorn U., Yaghoubi S., et al. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 32 suppl 2 (2005) S384-S403
147. Niu G., Gaut A.W., Ponto L.L., et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med 45 (2004) 445-449
148. Groot-Wassink T., Aboagye E.O., Wang Y., et al. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 9 (2004) 436-442
149. Liang Q., Satyamurthy N., Barrio J.R., et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 8 (2001) 1490-1498
150. MacLaren D.C., Gambhir S.S., Satyamurthy N., et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 6 (1999) 785-791
151. Tjuvajev J.G., Stockhammer G., Desai R., et al. Imaging the expression of transfected genes in vivo. Cancer Res 1555 (1995) 6126-6132
152. Tjuvajev J.G., Avril N., Oku T., et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58 (1998) 4333-4341
153. Gambhir S.S., Bauer E., Black M.E., et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 97 (2000) 2785-2790
154. Yaghoubi S.S., Wu L., Liang Q., et al. Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther 8 (2001) 1072-1080
155. Qiao J., Doubrovin M., Sauter B.V., et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 9 (2002) 168-175
156. Doubrovin M., Ponomarev V., Beresten T., et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 98 (2001) 9300-9305
157. Bhaumik S., Walls Z., Puttaraju M., et al. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing. Proc Natl Acad Sci U S A 101 (2004) 8693-8698
158. Luker G.D., Sharma V., Pica C.M., et al. Molecular imaging of protein-protein interactions: Controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer Res 1563 (2003) 1780-1788
159. Shu C.J., Guo S., Kim Y.J., et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci U S A 102 (2005) 17412-17417
160. Jacobs A., Voges J., Reszka R., et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
161. Peñuelas I., Mazzolini G., Boan J.F., et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1795
162. Fu D.X., Tanhehco Y.C., Chen J., et al. Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res 113 (2007) 1453-1458
163. Moeller B.J., Richardson R.A., and Dewhirst M.W. Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26 (2007) 241-248
164. Greco O., Marples B., Dachs G.U., et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 9 (2002) 1403-1411
165. Cohen B., Dafni H., Meir G., et al. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 7 (2005) 109-117
166. Genove G., DeMarco U., Xu H., et al. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med 11 (2005) 450-454
167. Gilad A.A., McMahon M.T., Walczak P., et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 25 (2007) 217-219
168. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 2179 (1994) 185-188
169. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
170. Shaked Y., and Kerbel R.S. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 167 (2007) 7055-7058
171. Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286
172. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 992 (2005) 1599-1610
173. Kiessling F., Greschus S., Lichy M.P., et al. Volumetric computed tomography (VCT): A new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nat Med 10 (2004) 1133-1138
174. Cai W., Rao J., Gambhir S.S., et al. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 5 (2006) 2624-2633
175. Tabruyn S.P., and Griffioen A.W. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 30355 (2007) 1-5
176. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
177. Cai W., Chen K., Mohamedali K.A., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 47 (2006) 2048-2056
178. Blankenberg F.G., Backer M.V., Levashova Z., et al. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33 (2006) 841-848
179. Blankenberg F.G., Mandl S., Cao Y.A., et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 45 (2004) 1373-1380
180. Cornelissen B., Oltenfreiter R., Kersemans V., et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 32 (2005) 431-436
181. Jayson G.C., Zweit J., Jackson A., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 294 (2002) 1484-1493
182. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2 (2002) 91-100
183. Stupack D.G., and Cheresh D.A. Integrins and angiogenesis. Curr Top Dev Biol 64 (2004) 207-238
184. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 3 (2006) 472-487
185. Beer A.J., Haubner R., Sarbia M., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 112 (2006) 3942-3949
186. Haubner R., Weber W.A., Beer A.J., et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2 (2005) e70
187. Winter P.M., Caruthers S.D., Kassner A., et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 1563 (2003) 5838-5843
188. Sipkins D.A., Cheresh D.A., Kazemi M.R., et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4 (1998) 623-626
189. Anderson S.A., Rader R.K., Westlin W.F., et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44 (2000) 433-439
190. Chen X., Conti P.S., and Moats R.A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 164 (2004) 8009-8014
191. Ellegala D.B., Leong-Poi H., Carpenter J.E., et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 22108 (2003) 336-341
192. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25 (2006) 9-34
193. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2 (2002) 657-672
194. Van de Wiele C., and Oltenfreiter R. Imaging probes targeting matrix metalloproteinases. Cancer Biother Radiopharm 21 (2006) 409-417
195. Choe Y.S., and Lee K.H. Targeted in vivo imaging of angiogenesis: Present status and perspectives. Curr Pharm Des 13 (2007) 17-31
196. Furumoto S., Takashima K., Kubota K., et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 30 (2003) 119-125
197. Giersing B.K., Rae M.T., CarballidoBrea M., et al. Synthesis and characterization of 111In-DTPA-N-TIMP-2: A radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem 12 (2001) 964-971
198. Medina O.P., Kairemo K., Valtanen H., et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res 25 (2005) 33-42
199. Bremer C., Tung C.H., and Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7 (2001) 743-748
200. Mahmood U., and Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2 (2003) 489-496
201. Funovics M., Montet X., Reynolds F., et al. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia 7 (2005) 904-911
202. Yang D.J., Kim K.D., Schechter N.R., et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm 17 (2002) 233-245
203. Nyati M.K., Morgan M.A., Feng F.Y., et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6 (2006) 876-885
204. Hicke B.J., Stephens A.W., Gould T., et al. Tumor targeting by an aptamer. J Nucl Med 47 (2006) 668-678
205. Lappin G., and Garner R.C. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2 (2003) 233-240
206. Kummar S., Kinders R., Rubinstein L., et al. Compressing drug development timelines in oncology using phase '0′ trials. Nat Rev Cancer 7 (2007) 131-139